Cystic phenotype and chronic kidney disease in autosomal dominant Alport syndrome

Teresa Bada-Bosch,Angel M Sevillano,María Teresa Sánchez-Calvin,Carmen Palma-Milla,Ignacio Alba de Cáceres,Francisco Díaz-Crespo,Hernando Trujillo,Marina Alonso,Clara Cases-Corona,Amir Shabaka,Juan Francisco Quesada-Espinosa,José Miguel Lezana-Rosales,Eduardo Gutiérrez,Gema Fernández-Juárez,Fernando Caravaca-Fontán,Manuel Praga
DOI: https://doi.org/10.1093/ndt/gfae002
IF: 7.1857
2024-01-04
Nephrology Dialysis Transplantation
Abstract:ABSTRACT Background Autosomal dominant Alport Syndrome (ADAS), also known as thin basement membrane disease (TBMD), is caused by pathogenic variants in the COL4A3 and COL4A4 genes. A cystic phenotype has been described in some patients with TBMD, but no genetic studies have been performed. We conducted a genetic and radiologic investigation in a cohort of ADAS patients to analyze the prevalence of multicystic kidney disease (MKD) and its association with chronic kidney disease (CKD). Methods This was a retrospective single-center cohort study. Thirty-one patients showing pathogenic or likely pathogenic variants in COL4A3 or COL4A4 from a cohort of 79 patients with persistent microscopic hematuria were included. Mean follow-up was 9.4 ± 9.6 years. The primary objective of the study was to determine the prevalence of MKD in the cohort of ADAS patients. Secondary objectives were to determine risk factors associated with an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 at the time of genetic and radiologic evaluation and to investigate the coexistence of other genetic abnormalities associated with familial hematuria and cystic kidney disease. Results MKD was found in 16 patients (52%). Mean number of cysts per kidney was 12.7 ± 5.5. No genetic abnormalities were found in a panel of 101 other genes related to familial hematuria, focal segmental glomerulosclerosis and cystic kidney disease. A greater number of patients with MKD had an eGFR <45 mL/min/1.73 m2 (63% vs 7%, P = .006) and more advanced CKD than patients without MKD. The annual rate of eGFR decline was greater in patients with MKD: –1.8 vs 0.06 mL/min/1.73 m2/year (P = .009). By multivariable linear regression analysis, the main determinants of eGFR change per year were time-averaged proteinuria (P = .002) and MKD (P = .02). Conclusion MKD is commonly found in ADAS and is associated with a worse kidney outcome. No pathogenic variants were found in genes other than COL4A3/COL4A4.
urology & nephrology,transplantation
What problem does this paper attempt to address?